

Aspirin Continuation or Interruption in Patients at Moderate Risk for Cardiovascular Events Undergoing Colonoscopy and/or Polypectomy

NCT07052799

| | |
|-------------------|---------------------------------|
| Status | RECRUITING |
| Phase | Phase 3 |
| Sponsor | Chinese University of Hong Kong |
| Enrollment | 2,514 participants |

Key Eligibility Criteria

Inclusion (1)

- patients receiving aspirin (80mg daily or more) for secondary prevention against cardiovascular diseases who require elective colonoscopy for colorectal cancer screening.

Exclusion (6)

- patients who received a coronary stent of any type within 6 months
- patients who had a cardiovascular event within 3 months
- patients who had concurrent use of anticoagulants (warfarin or NOAC) or other antiplatelet drugs (P2Y12 receptor antagonists)
- patient with bleeding diathesis e.g., hemophilia, von Willebrand's disease or coagulopathy from liver cirrhosis
- patient with terminal malignancies or medical illnesses.

... and 1 more (see full listing online)

Locations (1 total)

Prince of Wales Hospital, Hong Kong, Hong Kong